The Prostate Cancer Foundation has been a major catalyst for many of the scientific advances in prostate cancer research since 1993. PCF has awarded more than 2,250 projects that offer hope for improving outcomes in patients with prostate cancer. These high-impact projects include clinical research to evaluate new drugs, novel treatment strategies for prostate cancer and basic scientific research to better understand the biology of prostate cancer.
Challenge Awards
Ranging from $300,000 to $1,500,000 per year for 3 years, these awards will cover direct costs of the research. Teams may be assembled from one institution, or from several institutions and should be comprised of at least three highly experienced investigators capable of providing unique scientific expertise to the solution of a significant problem in prostate cancer research.
Creativity Awards
These two year awards for $300,000 support exceptionally novel projects with great potential to produce breakthroughs for detecting and treating prostate cancer. They are complementary and integrated with other PCF award programs.
Young Investigator Awards
The Young Investigator Awards offer career and project support for young (generally 35 and younger) proven investigators in postdoctoral fellowships or who have recently achieved junior faculty positions and are committing their lives to the field of prostate cancer.
Recognition Awards
PCF and its partners grant awards that recognize top presentations at international cancer research meetings. Recognition Awards go to investigators not currently funded by PCF who have a record of outstanding accomplishments in prostate cancer research.
TACTICAL Awards
PCF TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Awards provide up to $10 million over three years to support large-scale research projects led by qualified teams of academic scientists that specifically address the development of 21st Century therapies for lethal forms of prostate cancer.
Thirty-one years ago, PCF took its first steps in accelerating the funding for desperately needed prostate cancer research. In 1993, most people knew little about prostate cancer, and there were no well-known advocacy organizations for the disease. A lack of investment in the field meant not enough young scientists and physicians were choosing prostate cancer research careers, and the ones already in the field were too isolated to collaborate. Today, the PCF community has helped create a different world — one that focuses on ensuring patients will have the opportunity for more shared experiences, more time with loved ones, and a larger chance at a legacy that lies well beyond a prostate cancer diagnosis.